Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : NUV001
Therapeutic Area : Genetic Disease
Study Phase : Undisclosed
Recipient : LGD
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Dietary Supplement
Upfront Cash : Inapplicable
March 30, 2023
Lead Product(s) : NUV001
Therapeutic Area : Genetic Disease
Highest Development Status : Undisclosed
Recipient : LGD
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Nicotinamide Mononucleotide
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Undisclosed
Recipient : Abinopharm Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 30, 2021
Lead Product(s) : Nicotinamide Mononucleotide
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Undisclosed
Recipient : Abinopharm Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Viracide
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Recipient : The Herb, Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
October 22, 2020
Lead Product(s) : Viracide
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Recipient : The Herb, Inc
Deal Size : Inapplicable
Deal Type : Inapplicable